Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 425 of 520 entries
View as:

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT04526730 Org: User:
Start: 12/22/20 End: 06/15/28 Due: 06/15/29

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Phase: N/A Priority: Normal
NCT ID: NCT00798629 Org: User:
Start: 11/30/08 End: 04/30/12 Due: 04/30/13

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Phase: N/A Priority: Normal
NCT ID: NCT01432600 Org: User:
Start: 11/30/11 End: 08/31/16 Due: 08/31/17

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Phase: N/A Priority: Normal
NCT ID: NCT00127036 Org: User:
Start: 10/31/03 End: 12/31/10 Due: 12/31/11

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06047977 Org: User:
Start: 06/02/25 End: 12/01/27 Due: 12/01/28

Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness

Phase: N/A Priority: Normal
NCT ID: NCT01036321 Org: User:
Start: 12/11/09 End: 04/16/18 Due: 04/16/19

Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT00042731 Org: User:
Start: 07/31/02 End: 08/31/06 Due: 08/31/07

Study to Develop a Group-Based E-Health Intervention for YA Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT05048316 Org: User:
Start: 05/11/21 End: 01/06/22 Due: 01/06/23

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Phase: N/A Priority: Normal
NCT ID: NCT00434109 Org: User:
Start: 11/30/06 End: 02/29/12 Due: 02/28/13

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Phase: N/A Priority: Normal
NCT ID: NCT05809752 Org: User:
Start: 08/22/23 End: 03/31/26 Due: 03/31/27

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02945800 Org: User:
Start: 10/25/16 End: 02/28/26 Due: 02/28/27

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05378464 Org: User:
Start: 05/31/22 End: 12/31/26 Due: 12/31/27

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase: N/A Priority: Normal
NCT ID: NCT06236425 Org: User:
Start: 03/14/24 End: 08/31/26 Due: 08/31/27

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05170334 Org: User:
Start: 12/15/21 End: 01/31/28 Due: 01/31/29

Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01434550 Org: User:
Start: 03/31/12 End: 08/31/15 Due: 08/31/16

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Phase: N/A Priority: Normal
NCT ID: NCT06104592 Org: User:
Start: 11/08/23 End: 11/30/26 Due: 11/30/27

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Phase: N/A Priority: Normal
NCT ID: NCT04610671 Org: User:
Start: 10/26/20 End: 01/31/26 Due: 01/31/27

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05301283 Org: User:
Start: 05/18/22 End: 08/31/26 Due: 08/31/27

Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection

Phase: N/A Priority: Normal
NCT ID: NCT00751140 Org: User:
Start: 09/30/08 End: 04/30/12 Due: 04/30/13

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT00815685 Org: User:
Start: 07/31/07 End: 08/31/10 Due: 08/31/11

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06745882 Org: User:
Start: 01/21/25 End: 01/31/30 Due: 01/31/31

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

Phase: N/A Priority: Normal
NCT ID: NCT05768347 Org: User:
Start: 08/10/23 End: 07/31/26 Due: 07/31/27

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Phase: N/A Priority: Normal
NCT ID: NCT06760156 Org: User:
Start: 03/19/25 End: 01/31/28 Due: 01/31/29

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02829918 Org: User:
Start: 10/05/16 End: 05/24/23 Due: 05/24/24

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

Phase: N/A Priority: Normal
NCT ID: NCT06745895 Org: User:
Start: 10/21/24 End: 04/30/28 Due: 04/30/29